{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:49:28Z","timestamp":1781196568665,"version":"3.54.1"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00c3\u00a7\u00c3\u00a3o Carlos Chagas Filho de Amparo \u00c3\u00a0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/202-798\/2017"],"award-info":[{"award-number":["E-26\/202-798\/2017"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00c3\u00adfico e Tecnol\u00c3\u00b3gico","doi-asserted-by":"publisher","award":["CNPq-304565\/2016-4"],"award-info":[{"award-number":["CNPq-304565\/2016-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.blre.2020.100671","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T17:04:22Z","timestamp":1581527062000},"page":"100671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications"],"prefix":"10.1016","volume":"43","author":[{"given":"Paula Sabbo","family":"Bernardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauana Greicy Tonon","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Nestal","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Ciuvalschi","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2020.100671_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature."},{"key":"10.1016\/j.blre.2020.100671_bb0010","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0015","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bph.12183","article-title":"Targeting survival pathways in chronic myeloid leukaemia stem cells","volume":"169","author":"Sinclair","year":"2013","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.blre.2020.100671_bb0020","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.1158\/0008-5472.CAN-05-0303","article-title":"Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis","volume":"65","author":"Wang","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0025","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/j.1582-4934.2008.00549.x","article-title":"Transcriptional regulation of survivin by c-Myc in BCR\/ABL-transformed cells: implications in anti-leukaemic strategy","volume":"13","author":"Fang","year":"2009","journal-title":"J Cell Mol Med."},{"key":"10.1016\/j.blre.2020.100671_bb0030","first-page":"671702","article-title":"The interface between BCR-ABL-dependent and -independent resistance signaling pathways in chronic myeloid leukemia","volume":"2012","author":"Nestal de Moraes","year":"2012","journal-title":"Leuk Res Treatment"},{"key":"10.1016\/j.blre.2020.100671_bb0035","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science."},{"key":"10.1016\/j.blre.2020.100671_bb0040","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2009.09.006","article-title":"Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"290","author":"Lu","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.blre.2020.100671_bb0050","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cbt.4.4.1702","article-title":"Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin","volume":"4","author":"Demidenko","year":"2005","journal-title":"Cancer Biol Ther."},{"key":"10.1016\/j.blre.2020.100671_bb0055","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","article-title":"Chronic myelogenous leukemia: a concise update","volume":"82","author":"Kantarjian","year":"1993","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0060","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science."},{"key":"10.1016\/j.blre.2020.100671_bb0065","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100671_bb0070","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100671_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia","volume":"249","author":"Melo","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.blre.2020.100671_bb0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer Control."},{"key":"10.1016\/j.blre.2020.100671_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","article-title":"Imatinib resistance in CML","volume":"274","author":"Volpe","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.blre.2020.100671_bb0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.clml.2018.06.029","article-title":"Improving outcomes in chronic myeloid leukemia over time in the era of tyrosine kinase inhibitors","volume":"18","author":"Chopade","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.blre.2020.100671_bb0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2011.04.002","article-title":"Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase","volume":"82","author":"Rosti","year":"2012","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.blre.2020.100671_bb0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.exphem.2018.05.003","article-title":"Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib","volume":"64","author":"Nicolini","year":"2018","journal-title":"Exp Hematol."},{"key":"10.1016\/j.blre.2020.100671_bb0105","first-page":"18","article-title":"Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase","volume":"2","author":"Bose","year":"2013","journal-title":"Leuk Res Rep."},{"key":"10.1016\/j.blre.2020.100671_bb0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell."},{"key":"10.1016\/j.blre.2020.100671_bb0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14712598.2014.867323","article-title":"Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia","volume":"14","author":"Morotti","year":"2014","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.blre.2020.100671_bb0120","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest."},{"key":"10.1016\/j.blre.2020.100671_bb0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","article-title":"Leukemia stem cells: the root of chronic myeloid leukemia","volume":"6","author":"Zhou","year":"2015","journal-title":"Protein Cell."},{"key":"10.1016\/j.blre.2020.100671_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.leukres.2016.10.005","article-title":"Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice","volume":"51","author":"da Cunha","year":"2016","journal-title":"Leuk Res."},{"key":"10.1016\/j.blre.2020.100671_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23010119","article-title":"Towards comprehension of the ABCB1\/P-glycoprotein role in chronic myeloid leukemia","volume":"23","author":"Maia","year":"2018","journal-title":"Molecules."},{"key":"10.1016\/j.blre.2020.100671_bb0140","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20130067","article-title":"Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?","volume":"33","author":"Rumjanek","year":"2013","journal-title":"Biosci Rep."},{"key":"10.1016\/j.blre.2020.100671_bb0145","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/leu.2014.6","article-title":"MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure","volume":"28","author":"Agrawal","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100671_bb0150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"10.1016\/j.blre.2020.100671_bb0155","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat Med."},{"key":"10.1016\/j.blre.2020.100671_bb0160","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2006.03.007","article-title":"Structural, functional and therapeutic biology of survivin","volume":"244","author":"Sah","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.blre.2020.100671_bb0165","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/77929","article-title":"Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement","volume":"7","author":"Verdecia","year":"2000","journal-title":"Nat Struct Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0170","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ceb.2006.08.015","article-title":"The case for survivin as a regulator of microtubule dynamics and cell-death decisions","volume":"18","author":"Altieri","year":"2006","journal-title":"Curr Opin Cell Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0175","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1021\/bi001603q","article-title":"An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7","volume":"40","author":"Shin","year":"2001","journal-title":"Biochemistry."},{"key":"10.1016\/j.blre.2020.100671_bb0180","first-page":"5315","article-title":"IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs","volume":"58","author":"Tamm","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0185","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1093\/emboj\/cdg263","article-title":"HBXIP functions as a cofactor of survivin in apoptosis suppression","volume":"22","author":"Marusawa","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.blre.2020.100671_bb0190","doi-asserted-by":"crossref","first-page":"34087","DOI":"10.1074\/jbc.C400236200","article-title":"An IAP-IAP complex inhibits apoptosis","volume":"279","author":"Dohi","year":"2004","journal-title":"J Biol Chem."},{"key":"10.1016\/j.blre.2020.100671_bb0195","doi-asserted-by":"crossref","first-page":"23130","DOI":"10.1074\/jbc.M300957200","article-title":"Direct interaction between survivin and Smac\/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis","volume":"278","author":"Song","year":"2003","journal-title":"J Biol Chem."},{"key":"10.1016\/j.blre.2020.100671_bb0200","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4161\/cc.3.9.1093","article-title":"An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy","volume":"3","author":"Zangemeister-Wittke","year":"2004","journal-title":"Cell Cycle."},{"key":"10.1016\/j.blre.2020.100671_bb0205","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/25141","article-title":"Control of apoptosis and mitotic spindle checkpoint by survivin","volume":"396","author":"Li","year":"1998","journal-title":"Nature."},{"key":"10.1016\/j.blre.2020.100671_bb0210","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4161\/cc.6.5.3902","article-title":"Survivin\u2019s dual role: an export\u2019s view","volume":"6","author":"Knauer","year":"2007","journal-title":"Cell Cycle."},{"key":"10.1016\/j.blre.2020.100671_bb0215","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ijc.20768","article-title":"Nuclear or cytoplasmic expression of survivin: what is the significance?","volume":"114","author":"Li","year":"2005","journal-title":"Int J Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0220","first-page":"129","article-title":"Dynamic changes to survivin subcellular localization are initiated by DNA damage","volume":"3","author":"Asumen","year":"2010","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.blre.2020.100671_bb0225","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1172\/JCI200422222","article-title":"Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis","volume":"114","author":"Dohi","year":"2004","journal-title":"J Clin Invest."},{"key":"10.1016\/j.blre.2020.100671_bb0230","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2007.07.045","article-title":"Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together","volume":"131","author":"Jeyaprakash","year":"2007","journal-title":"Cell."},{"key":"10.1016\/j.blre.2020.100671_bb0235","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/onc.2008.303","article-title":"New wirings in the survivin networks","volume":"27","author":"Altieri","year":"2008","journal-title":"Oncogene."},{"key":"10.1016\/j.blre.2020.100671_bb0240","first-page":"43","article-title":"Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation","volume":"152","author":"Adida","year":"1998","journal-title":"Am J Pathol."},{"key":"10.1016\/j.blre.2020.100671_bb0245","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V98.7.2091","article-title":"Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis","volume":"98","author":"Fukuda","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0250","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","article-title":"Characterization of chronic myeloid leukemia stem cells","volume":"86","author":"Gerber","year":"2011","journal-title":"Am J Hematol."},{"key":"10.1016\/j.blre.2020.100671_bb0255","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.yexcr.2018.07.017","article-title":"HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1","volume":"370","author":"Bamodu","year":"2018","journal-title":"Exp Cell Res."},{"key":"10.1016\/j.blre.2020.100671_bb0260","doi-asserted-by":"crossref","first-page":"R349","DOI":"10.1186\/ar1498","article-title":"Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis","volume":"7","author":"Bokarewa","year":"2005","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.blre.2020.100671_bb0265","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/jid.2011.279","article-title":"Survivin: a dual player in healthy and diseased skin","volume":"132","author":"Dallaglio","year":"2012","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.blre.2020.100671_bb0270","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1349-7006.2008.00870.x","article-title":"Cancer cells survive with survivin","volume":"99","author":"Yamamoto","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.blre.2020.100671_bb0275","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery","volume":"8","author":"Altieri","year":"2008","journal-title":"Nat Rev Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0280","first-page":"315","article-title":"Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors","volume":"21","author":"Sui","year":"2002","journal-title":"Int J Oncol."},{"key":"10.1016\/j.blre.2020.100671_bb0285","first-page":"557","article-title":"Intracellular localization of survivin determines biological behavior in colorectal cancer","volume":"22","author":"Qi","year":"2009","journal-title":"Oncol Rep."},{"key":"10.1016\/j.blre.2020.100671_bb0290","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.cellsig.2015.09.013","article-title":"FOXM1 targets XIAP and survivin to modulate breast cancer survival and chemoresistance","volume":"27","author":"Nestal De Moraes","year":"2015","journal-title":"Cell Signal."},{"key":"10.1016\/j.blre.2020.100671_bb0295","first-page":"1921","article-title":"Prognostic significance of survivin expression in diffuse large B-cell lymphomas","volume":"96","author":"Adida","year":"2000","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0300","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/07357907.2012.672844","article-title":"Centroblastic diffuse large B cell lymphoma displays distinct expression pattern and prognostic role of apoptosis resistance related proteins","volume":"30","author":"Faccion","year":"2012","journal-title":"Cancer Invest."},{"key":"10.1016\/j.blre.2020.100671_bb0305","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/1871520611313020019","article-title":"The therapeutical potential of a novel pterocarpanquinone LQB-118 to target inhibitor of apoptosis proteins in acute myeloid leukemia cells","volume":"13","author":"de Souza Reis","year":"2013","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.blre.2020.100671_bb0310","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1532\/IJH97.04031","article-title":"Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias","volume":"80","author":"Sugahara","year":"2004","journal-title":"Int J Hematol."},{"key":"10.1016\/j.blre.2020.100671_bb0315","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","article-title":"Regulation of survivin expression through Bcr-Abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells","volume":"107","author":"Carter","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0320","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1007\/s13277-015-3865-5","article-title":"Survivin splice variants and their diagnostic significance","volume":"36","author":"Sah","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0325","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02982021","article-title":"Expression of the antiapoptosis gene survivin in human leukemia","volume":"75","author":"Mori","year":"2002","journal-title":"Int J Hematol."},{"key":"10.1016\/j.blre.2020.100671_bb0330","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2011.01.010","article-title":"Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses","volume":"139","author":"Speletas","year":"2011","journal-title":"Clin Immunol."},{"key":"10.1016\/j.blre.2020.100671_bb0335","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2004.10.034","article-title":"Survivin expression in chronic myeloid leukemia","volume":"225","author":"Conte","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.blre.2020.100671_bb0340","first-page":"471","article-title":"Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia","volume":"26","author":"Reis","year":"2011","journal-title":"Oncol Rep."},{"key":"10.1016\/j.blre.2020.100671_bb0345","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.leu.2403621","article-title":"The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients","volume":"19","author":"Andersen","year":"2005","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100671_bb0350","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.4049\/jimmunol.175.4.2709","article-title":"Spontaneous immunity against Bcl-xL in cancer patients","volume":"175","author":"Andersen","year":"2005","journal-title":"J Immunol."},{"key":"10.1016\/j.blre.2020.100671_bb0355","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/0008-5472.CAN-07-0302","article-title":"BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells","volume":"67","author":"Brauer","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0360","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100671_bb0365","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/1521-1878(200011)22:11<961::AID-BIES1>3.0.CO;2-T","article-title":"Catenins, Wnt signaling and cancer","volume":"22","author":"Barker","year":"2000","journal-title":"Bioessays."},{"key":"10.1016\/j.blre.2020.100671_bb0370","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/156800911794328420","article-title":"The gamma catenin\/CBP complex maintains survivin transcription in beta-catenin deficient\/depleted cancer cells","volume":"11","author":"Kim","year":"2011","journal-title":"Curr Cancer Drug Targets."},{"key":"10.1016\/j.blre.2020.100671_bb0375","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.281.5382.1509","article-title":"Identification of c-MYC as a target of the APC pathway","volume":"281","author":"He","year":"1998","journal-title":"Science."},{"key":"10.1016\/j.blre.2020.100671_bb0380","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3892\/ijmm.2012.1207","article-title":"Downregulation of gamma-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through beta-catenin inhibition","volume":"31","author":"Niu","year":"2013","journal-title":"Int J Mol Med."},{"key":"10.1016\/j.blre.2020.100671_bb0385","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428190601075973","article-title":"A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase","volume":"48","author":"Quintas-Cardama","year":"2007","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.blre.2020.100671_bb0390","first-page":"1613","article-title":"Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells","volume":"25","author":"Nestal De Moraes","year":"2011","journal-title":"Oncol Rep."},{"key":"10.1016\/j.blre.2020.100671_bb0395","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0400","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML","author":"Vetrie","year":"2020","journal-title":"Nat Rev Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0405","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat Med."},{"key":"10.1016\/j.blre.2020.100671_bb0410","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5114\/pjp.2017.73925","article-title":"Survivin in breast lesions: immunohistochemical analysis of 196 cases","volume":"68","author":"Adamkov","year":"2017","journal-title":"Pol J Pathol."},{"key":"10.1016\/j.blre.2020.100671_bb0415","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3171\/2016.11.JNS162326","article-title":"Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide","volume":"128","author":"Saito","year":"2018","journal-title":"J Neurosurg."},{"key":"10.1016\/j.blre.2020.100671_bb0420","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.leukres.2012.08.014","article-title":"Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells","volume":"36","author":"Bernardo","year":"2012","journal-title":"Leuk Res."},{"key":"10.1016\/j.blre.2020.100671_bb0425","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/sj.bjc.6600776","article-title":"Prognostic importance of survivin in breast cancer","volume":"88","author":"Kennedy","year":"2003","journal-title":"Br J Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0430","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms14035338","article-title":"Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications","volume":"14","author":"Corrado","year":"2013","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.blre.2020.100671_bb0435","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/sj.bjc.6604978","article-title":"Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential","volume":"100","author":"Khan","year":"2009","journal-title":"Br J Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0440","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12964-015-0086-x","article-title":"Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism","volume":"13","author":"Raimondo","year":"2015","journal-title":"Cell Commun Signal."},{"key":"10.1016\/j.blre.2020.100671_bb0445","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/cas.12566","article-title":"Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type","volume":"106","author":"de Souza","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.blre.2020.100671_bb0450","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3892\/ol.2015.3913","article-title":"Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy","volume":"11","author":"Huang","year":"2016","journal-title":"Oncol Lett."},{"key":"10.1016\/j.blre.2020.100671_bb0455","doi-asserted-by":"crossref","first-page":"e0571","DOI":"10.1097\/MD.0000000000010571","article-title":"Prognostic role of survivin in patients with glioma","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.blre.2020.100671_bb0460","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3109\/10428194.2014.1003052","article-title":"Prognostic value of inhibitor of apoptosis protein family expression in patients with acute myeloid leukemia","volume":"56","author":"Pluta","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.blre.2020.100671_bb0465","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clinbiochem.2011.08.1147","article-title":"Prognostic significance of survivin and tumor necrosis factor-alpha in adult acute lymphoblastic leukemia","volume":"45","author":"Ahmed","year":"2012","journal-title":"Clin Biochem."},{"key":"10.1016\/j.blre.2020.100671_bb0470","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13402-017-0361-5","article-title":"p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors","volume":"41","author":"Faccion","year":"2018","journal-title":"Cell Oncol (Dordr)."},{"key":"10.1016\/j.blre.2020.100671_bb0475","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s12253-011-9401-z","article-title":"Lack of prognostic significance of survivin in pediatric medulloblastoma","volume":"17","author":"Faccion","year":"2011","journal-title":"Pathol Oncol Res."},{"key":"10.1016\/j.blre.2020.100671_bb0480","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0485","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/10428190500052131","article-title":"Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients","volume":"46","author":"Hernandez-Boluda","year":"2005","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.blre.2020.100671_bb0490","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjh.12663","article-title":"Differential expression of BIRC family genes in chronic myeloid leukaemia--BIRC3 and BIRC8 as potential new candidates to identify disease progression","volume":"164","author":"Glodkowska-Mrowka","year":"2014","journal-title":"Br J Haematol."},{"key":"10.1016\/j.blre.2020.100671_bb0495","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1089\/gtmb.2018.0152","article-title":"Expression of survivin and its splice variants in pediatric acute lymphoblastic leukemia","volume":"22","author":"Eren-Keles","year":"2018","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.blre.2020.100671_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082858","article-title":"Association of survivin polymorphisms with tumor susceptibility: a meta-analysis","volume":"8","author":"Zhu","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.blre.2020.100671_bb0505","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s13277-013-1229-6","article-title":"Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies","volume":"35","author":"Xu","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0510","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10147-019-01408-y","article-title":"Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case-control studies","volume":"24","author":"Moazeni-Roodi","year":"2019","journal-title":"Int J Clin Oncol."},{"key":"10.1016\/j.blre.2020.100671_bb0515","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1089\/1044549041474788","article-title":"A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells","volume":"23","author":"Xu","year":"2004","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0520","first-page":"2941","article-title":"Correlation between survivin polymorphism and acute leukemia of children","volume":"15","author":"Li","year":"2018","journal-title":"Exp Ther Med."},{"key":"10.1016\/j.blre.2020.100671_bb0525","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.leukres.2007.11.013","article-title":"Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia","volume":"32","author":"Wagner","year":"2008","journal-title":"Leuk Res."},{"key":"10.1016\/j.blre.2020.100671_bb0530","doi-asserted-by":"crossref","first-page":"19532","DOI":"10.1074\/jbc.M109.078584","article-title":"Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells","volume":"285","author":"Porro","year":"2010","journal-title":"J Biol Chem."},{"key":"10.1016\/j.blre.2020.100671_bb0535","first-page":"127","article-title":"Overview of tumor cell chemoresistance mechanisms","volume":"111","author":"Gatti","year":"2005","journal-title":"Methods Mol Med."},{"key":"10.1016\/j.blre.2020.100671_bb0540","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/bjc.2016.5","article-title":"Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma","volume":"114","author":"Werner","year":"2016","journal-title":"Br J Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0545","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.leukres.2013.06.014","article-title":"XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells","volume":"37","author":"Silva","year":"2013","journal-title":"Leuk Res."},{"key":"10.1016\/j.blre.2020.100671_bb0550","first-page":"925","article-title":"P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells","volume":"39","author":"Souza","year":"2011","journal-title":"Int J Oncol."},{"key":"10.1016\/j.blre.2020.100671_bb0555","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1248\/bpb.30.2279","article-title":"The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells","volume":"30","author":"Liu","year":"2007","journal-title":"Biol Pharm Bull."},{"key":"10.1016\/j.blre.2020.100671_bb0560","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1167\/iovs.07-1135","article-title":"Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma","volume":"49","author":"Maat","year":"2008","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"10.1016\/j.blre.2020.100671_bb0565","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/carcin\/bgr205","article-title":"Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells","volume":"32","author":"Nakamura","year":"2011","journal-title":"Carcinogenesis."},{"key":"10.1016\/j.blre.2020.100671_bb0570","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat Rev Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0575","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/cas.12540","article-title":"Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells","volume":"105","author":"Taniguchi","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.blre.2020.100671_bb0580","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cbi.2016.04.011","article-title":"Targeting HSP90\/Survivin using a cell permeable structure based peptido-mimetic shepherdin in retinoblastoma","volume":"252","author":"Venkatesan","year":"2016","journal-title":"Chem Biol Interact."},{"key":"10.1016\/j.blre.2020.100671_bb0585","doi-asserted-by":"crossref","first-page":"13103","DOI":"10.1073\/pnas.240390697","article-title":"Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin","volume":"97","author":"O\u2019Connor","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.blre.2020.100671_bb0590","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.bbrc.2017.01.160","article-title":"High-throughput screening for Survivin and Borealin interaction inhibitors in hepatocellular carcinoma","volume":"484","author":"Yue","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.blre.2020.100671_bb0595","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.devcel.2006.11.001","article-title":"Chromosomal enrichment and activation of the aurora B pathway are coupled to spatially regulate spindle assembly","volume":"12","author":"Kelly","year":"2007","journal-title":"Dev Cell."},{"key":"10.1016\/j.blre.2020.100671_bb0600","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.cub.2019.03.051","article-title":"Aurora B-INCENP localization at centromeres\/inner kinetochores is required for chromosome bi-orientation in budding yeast","volume":"29","author":"Garcia-Rodriguez","year":"2019","journal-title":"Curr Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0605","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jmb.2010.10.046","article-title":"Structural characterization of HBXIP: the protein that interacts with the anti-apoptotic protein survivin and the oncogenic viral protein HBx","volume":"405","author":"Garcia-Saez","year":"2011","journal-title":"J Mol Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0610","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1083\/jcb.151.7.1575","article-title":"Human survivin is a kinetochore-associated passenger protein","volume":"151","author":"Skoufias","year":"2000","journal-title":"J Cell Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0615","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1158\/0008-5472.CAN-06-1886","article-title":"HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis","volume":"66","author":"Fujii","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0620","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1535-7163.MCT-05-0436","article-title":"Targeted therapy by disabling crossroad signaling networks: the survivin paradigm","volume":"5","author":"Altieri","year":"2006","journal-title":"Mol Cancer Ther."},{"key":"10.1016\/j.blre.2020.100671_bb0625","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18632\/genesandcancer.111","article-title":"Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia","volume":"7","author":"Chakraborty","year":"2016","journal-title":"Genes Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0630","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.18632\/oncotarget.14324","article-title":"Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.blre.2020.100671_bb0635","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood-2017-10-810986","article-title":"Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response","volume":"132","author":"Bhatia","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0640","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/ijc.28434","article-title":"Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling","volume":"134","author":"Yang","year":"2014","journal-title":"Int J Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112318","article-title":"Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763\/AS703569 and PHA-739358 in BCR-ABL transformed cells","volume":"9","author":"Illert","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.blre.2020.100671_bb0650","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0655","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2147\/OTT.S33374","article-title":"Survivin - biology and potential as a therapeutic target in oncology","volume":"6","author":"Cheung","year":"2013","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.blre.2020.100671_bb0660","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/med.21547","article-title":"Therapeutic strategies involving survivin inhibition in cancer","volume":"39","author":"Martinez-Garcia","year":"2019","journal-title":"Med Res Rev."},{"key":"10.1016\/j.blre.2020.100671_bb0665","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10637-010-9453-z","article-title":"LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells","volume":"29","author":"Maia","year":"2011","journal-title":"Invest New Drugs."},{"key":"10.1016\/j.blre.2020.100671_bb0670","doi-asserted-by":"crossref","first-page":"805639","DOI":"10.1155\/2013\/805639","article-title":"Apoptosis induced by tanshinone IIA and cryptotanshinone is mediated by distinct JAK\/STAT3\/5 and SHP1\/2 signaling in chronic myeloid leukemia K562 cells","volume":"2013","author":"Jung","year":"2013","journal-title":"Evid Based Complement Alternat Med."},{"key":"10.1016\/j.blre.2020.100671_bb0675","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s12013-013-9670-0","article-title":"Inactivation of HDAC3 and STAT3 is critically involved in 1-stearoyl-sn-glycero-3-phosphocholine-induced apoptosis in chronic myelogenous leukemia K562 cells","volume":"67","author":"Jung","year":"2013","journal-title":"Cell Biochem Biophys."},{"key":"10.1016\/j.blre.2020.100671_bb0680","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","article-title":"Janus kinase 2: a critical target in chronic myelogenous leukemia","volume":"66","author":"Samanta","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0685","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00277-010-0996-z","article-title":"Inactivation of PI3k\/Akt signaling pathway and activation of caspase-3 are involved in tanshinone I-induced apoptosis in myeloid leukemia cells in vitro","volume":"89","author":"Liu","year":"2010","journal-title":"Ann Hematol."},{"key":"10.1016\/j.blre.2020.100671_bb0690","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00204-014-1226-6","article-title":"Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway","volume":"89","author":"Li","year":"2015","journal-title":"Arch Toxicol."},{"key":"10.1016\/j.blre.2020.100671_bb0695","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.7150\/jca.17688","article-title":"Tuberostemonine reverses multidrug resistance in chronic myelogenous leukemia cells K562\/ADR","volume":"8","author":"Wang","year":"2017","journal-title":"J Cancer."},{"key":"10.1016\/j.blre.2020.100671_bb0700","doi-asserted-by":"crossref","first-page":"13239","DOI":"10.1073\/pnas.0405407101","article-title":"Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression","volume":"101","author":"Chang","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.blre.2020.100671_bb0705","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/10428190601186143","article-title":"Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin","volume":"48","author":"Mak","year":"2007","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.blre.2020.100671_bb0710","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10637-014-0198-y","article-title":"Phase I study of the novel Cdc2\/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias","volume":"33","author":"Tibes","year":"2015","journal-title":"Invest New Drugs."},{"key":"10.1016\/j.blre.2020.100671_bb0715","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0720","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3892\/ijo.2015.2994","article-title":"CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation","volume":"47","author":"Fang","year":"2015","journal-title":"Int J Oncol."},{"key":"10.1016\/j.blre.2020.100671_bb0725","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.18632\/oncotarget.2837","article-title":"HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.blre.2020.100671_bb0730","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-08-0721","article-title":"Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells","volume":"14","author":"Fiskus","year":"2008","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0735","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0740","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1349-7006.2010.01834.x","article-title":"Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models","volume":"102","author":"Nakahara","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.blre.2020.100671_bb0745","first-page":"179","article-title":"Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter","volume":"3","author":"Cheng","year":"2012","journal-title":"Int J Biochem Mol Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0750","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-012-1868-0","article-title":"The \u201csurvivin suppressants\u201d NSC 80467 and YM155 induce a DNA damage response","volume":"70","author":"Glaros","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.blre.2020.100671_bb0755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038625","article-title":"YM155 induces EGFR suppression in pancreatic cancer cells","volume":"7","author":"Na","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.blre.2020.100671_bb0760","series-title":"WebSite accessed in September","author":"clinicaltrials.gov","year":"2019"},{"key":"10.1016\/j.blre.2020.100671_bb0765","first-page":"3676","article-title":"FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties","volume":"9","author":"Wang","year":"2017","journal-title":"Am J Transl Res."},{"key":"10.1016\/j.blre.2020.100671_bb0770","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045571","article-title":"A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity","volume":"7","author":"Ling","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.blre.2020.100671_bb0775","first-page":"370","article-title":"Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?","volume":"7","author":"Li","year":"2017","journal-title":"Am J Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0780","first-page":"1765","article-title":"FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models","volume":"7","author":"Ling","year":"2015","journal-title":"Am J Transl Res."},{"key":"10.1016\/j.blre.2020.100671_bb0785","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1158\/1535-7163.MCT-08-0161","article-title":"SPC3042: a proapoptotic survivin inhibitor","volume":"7","author":"Hansen","year":"2008","journal-title":"Mol Cancer Ther."},{"key":"10.1016\/j.blre.2020.100671_bb0790","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/MPH.0b013e3182a8f58f","volume":"36","author":"Raetz","year":"2014","journal-title":"J Pediatr Hematol Oncol."},{"key":"10.1016\/j.blre.2020.100671_bb0795","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s10637-013-9935-x","article-title":"Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)","volume":"31","author":"Erba","year":"2013","journal-title":"Invest New Drugs."},{"key":"10.1016\/j.blre.2020.100671_bb0800","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbrc.2010.01.113","article-title":"Identification of a small-molecule inhibitor of the interaction between Survivin and Smac\/DIABLO","volume":"393","author":"Oikawa","year":"2010","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.blre.2020.100671_bb0805","doi-asserted-by":"crossref","first-page":"13791","DOI":"10.1073\/pnas.2434345100","article-title":"Regulation of survivin function by Hsp90","volume":"100","author":"Fortugno","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.blre.2020.100671_bb0810","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1158\/1535-7163.MCT-12-0550","article-title":"Suppression of survivin induced by a BCR-ABL\/JAK2\/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs","volume":"12","author":"Stella","year":"2013","journal-title":"Mol Cancer Ther."},{"key":"10.1016\/j.blre.2020.100671_bb0815","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","article-title":"Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients","volume":"28","author":"Samanta","year":"2009","journal-title":"Oncogene."},{"key":"10.1016\/j.blre.2020.100671_bb0820","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrg2290","article-title":"Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?","volume":"9","author":"Filipowicz","year":"2008","journal-title":"Nat Rev Genet."},{"key":"10.1016\/j.blre.2020.100671_bb0825","doi-asserted-by":"crossref","first-page":"14117","DOI":"10.1007\/s13277-016-5205-9","article-title":"miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-kappaB target genes","volume":"37","author":"Farhadi","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.blre.2020.100671_bb0830","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13046-019-1059-5","article-title":"MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer","volume":"38","author":"Zhang","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0835","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2013-07-516807","article-title":"The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem\/progenitor cells","volume":"123","author":"Rothe","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100671_bb0840","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/annonc\/mdt249","article-title":"A phase I\/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"24","author":"Kelly","year":"2013","journal-title":"Ann Oncol."},{"key":"10.1016\/j.blre.2020.100671_bb0845","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1158\/1078-0432.CCR-10-1932","article-title":"Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study","volume":"16","author":"Talbot","year":"2010","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.blre.2020.100671_bb0850","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00262-016-1890-x","article-title":"Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma","volume":"65","author":"Fenstermaker","year":"2016","journal-title":"Cancer Immunol Immunother."},{"key":"10.1016\/j.blre.2020.100671_bb0855","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-013-1516-5","article-title":"Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors","volume":"63","author":"Lennerz","year":"2014","journal-title":"Cancer Immunol Immunother."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:23:29Z","timestamp":1759436609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":171,"alternative-id":["S0268960X20300217"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100671","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100671"}}